2. Search Result
Search Result
Results for "

Rabies

" in MedChemExpress (MCE) Product Catalog:

27

Inhibitors & Agonists

4

Biochemical Assay Reagents

9

Peptides

7

Inhibitory Antibodies

3

Natural
Products

6

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-18980
    Rottlerin
    20+ Cited Publications

    Mallotoxin; NSC 56346; NSC 94525

    		 PKC Autophagy Apoptosis HIV RABV Infection Cancer
    Rottlerin, a natural product purified from Mallotus Philippinensis, is a specific PKC inhibitor, with IC50 values for PKCδ of 3-6 μM, PKCα,β,γ of 30-42 μM, PKCε,η,ζ of 80-100 μM. Rottlerin acts as a direct mitochondrial uncoupler, and stimulates autophagy by targeting a signaling cascade upstream of mTORC1. Rottlerin induces apoptosis via caspase 3 activation . Rottlerin inhibits HIV-1 integration and Rabies virus (RABV) infection .
    Rottlerin
  • HY-P5623A
    RVG-Cys

    RVG29-Cys; RDP-Cys; Rabies Virus Glycoprotein-29-Cys

    		 RABV Others
    RVG-Cys (RVG29-Cys) is a peptide derived from rabies virus glycoprotein (RVG29) with Cys attached to facilitate subsequent conjugation. RVG-Cys enhances the specific targeted delivery of proteins in brain tissue and neurons .
    RVG-Cys
  • HY-P5623
    RVG
    1 Publications Verification

    RVG29; RDP; Rabies Virus Glycoprotein-29

    		 nAChR Interleukin Related Neurological Disease Inflammation/Immunology
    RVG (RVG29) is a blood-brain barrier-permeable peptide derived from rabies virus glycoprotein, which binds to the α-7 subunit of neuronal nicotinic acetylcholine receptor (AchR). RVG efficiently delivers drugs to nerve cells and antigen-presenting cells in a targeted manner, and enhances the efficiency of antigen presentation and drug delivery .
    RVG
  • HY-P4086
    Chimeric Rabies Virus Glycoprotein Fragment (RVG-9R)

    		RABV nAChR Neurological Disease Cancer
    Chimeric Rabies Virus Glycoprotein Fragment (RVG-9R) is a cell-penetrating peptide that is synthesized by adding nona-arginine motif to the carboxy terminus of RVG (rabies virus glycoprotein). Chimeric Rabies Virus Glycoprotein Fragment (RVG-9R) binds to
    nAChR     on neuronal cells to mediate receptor-mediated endocytosis and targeted siRNA delivery. Chimeric Rabies Virus Glycoprotein Fragment (RVG-9R) protects complexed siRNA from degradation, enhances transcellular siRNA delivery in neuronal cells, and promotes efficient, pecific gene silencing. Chimeric Rabies Virus Glycoprotein Fragment (RVG-9R) can be used for the researches of neurological disease and cancer .
    Chimeric Rabies Virus Glycoprotein Fragment (RVG-9R)
  • HY-P5623A1
    RVG-Cys acetate

    RVG29-Cys acetate; RDP-Cys acetate; Rabies Virus Glycoprotein-29-Cys acetate

    		 RABV Others
    RVG-Cys (RVG29-Cys) acetate is a peptide derived from rabies virus glycoprotein (RVG29) with Cys attached to facilitate subsequent conjugation. RVG-Cys acetate enhances the specific targeted delivery of proteins in brain tissue and neurons .
    RVG-Cys acetate
  • HY-172706
    DSPE-PEG5000-RVG29

    		Liposome nAChR Neurological Disease
    DSPE-PEG5000-RVG29 is a PEG compound which composed of DSPE and a Rabies virus glycoprotein 29 (RVG29). RVG29 can bind specifically to the nicotinic acetylcholine receptor (nAChR) at the blood-brain barrier (BBB) and cross over the BBB .
    DSPE-PEG5000-RVG29
  • HY-P0285
    Rabies Virus Glycoprotein
    1 Publications Verification

    		 RABV Infection
    Rabies Virus Glycoprotein is a 29-amino-acid cell penetrating peptide derived from a rabies virus glycoprotein that can cross the blood-brain barrier (BBB) and enter brain cells.
    Rabies Virus Glycoprotein
  • HY-107620
    PD 198306

    		MEK Neurological Disease
    PD 198306 is a selective MAPK/ERK-kinase (MEK) inhibitor. PD 198306 results in an observable reduction in the Streptozocin induced increase in the level of active ERK1 and 2. Antihyperalgesic effects .
    PD 198306
  • HY-P99811
    Rafivirumab

    CR57

    		 RABV Infection
    Rafivirumab (CR57) is an anti-rabies virus monoclonal antibody for the prophylaxis of rabies. Rafivirumab has neutralizing potency against a broad spectrum of RABV variants. Rafivirumab can be used for research of cocktails .
    Rafivirumab
  • HY-P99727
    Mazorelvimab

    CTB012

    		 RABV Infection
    Mazorelvimab (CTB012) is an anti-rabies humanized IgG1κ monoclonal antibody that binds to the non-overlapping epitopes on the rabies virus (RABV) glycoprotein. Mazorelvimab binds to highly discontinuous conserved residues that are not in or near antigenic site III. Mezagitamab has potential application in the prevention of rabies .
    Mazorelvimab
  • HY-172705
    DSPE-PEG2000-RVG29

    		Liposome nAChR Neurological Disease
    DSPE-PEG2000-RVG29 is a PEG conjugate composed of DSPE and rabies virus glycoprotein 29 (RVG29). RVG29 specifically binds to nicotinic acetylcholine receptors (nAChR) at the blood-brain barrier (BBB), crosses the BBB, and mediates receptor-dependent transcytosis. DSPE-PEG2000-RVG29 can be used for brain-targeted drug delivery, surface modification of nanocarriers, as well as gene and nucleic acid delivery. DSPE-PEG2000-RVG29 is applicable to research related to hypoxic-ischemic brain injury, Parkinson's disease, and other conditions .
    DSPE-PEG2000-RVG29
  • HY-P99624
    Foravirumab

    CR4098

    		 RABV Infection
    Foravirumab (CR4098) is a monoclonal antibody against rabies virus glycoprotein antigenic site III .
    Foravirumab
  • HY-P99792
    Ormutivimab

    NM57; rhRIG

    		 RABV Infection
    Ormutivimab (rhRIG) is a recombinant human monoclonal antibody, targeting rabies virus. Ormutivimab neutralizes a variety of rabies virus strains. Ormutivimab exhibits potent potency against rabies post-exposure prophylaxis (PEP) model .
    Ormutivimab
  • HY-P5623B
    RVG TFA
    1 Publications Verification

    RVG29 TFA; RDP TFA; Rabies Virus Glycoprotein-29 TFA

    		 Bacterial Infection
    RVG TFA is a peptide derived from Rabies Virus Glycoprotein that binds to the α-7 subunit of nicotinic acetylcholine receptors (AchR) of neuronal cells. RVG enhances delivery of Mycobacterium tuberculosis antigens to antigen-presenting cells .
    RVG TFA
  • HY-P0285A
    Rabies Virus Glycoprotein TFA
    1 Publications Verification

    		 RABV Infection
    Rabies Virus Glycoprotein (TFA) is a 29-amino-acid cell penetrating peptide derived from a rabies virus glycoprotein that can cross the blood-brain barrier (BBB) and enter brain cells .
    Rabies Virus Glycoprotein TFA
  • HY-P99513
    Zamerovimab

    CTB011

    		 RABV Infection
    Zamerovimab (CTB011) is an anti-rabies humanized IgG1κ monoclonal antibody that binds to the non-overlapping epitopes on the rabies virus (RABV) glycoprotein. Zamerovimab targets residues at and near antigenic site III. Zamerovimab can be used in rabies studies .
    Zamerovimab
  • HY-P99856
    Docaravimab

    62-71-3

    		 RABV Infection
    Docaravimab is an antibody, targeting ERA (Evelyn-Rockitniki-Abelseth) glycoprotein ectodomain epitope G-III. Docaravimab can be used in research of Rabies .
    Docaravimab
  • HY-133735A
    GRP-60367 hydrochloride
    1 Publications Verification

    		 RABV Infection
    GRP-60367 hydrochloride is a first-in-class small-molecule rabies virus (RABV) entry inhibitor with nanomolar potency against some RABV strains. GRP-60367 hydrochloride specifically targets the RABV G protein .
    GRP-60367 hydrochloride
  • HY-N14107
    Cinnabarin

    		Bacterial Endogenous Metabolite Infection
    Cinnabarin is a natural phenoxazinone red pigment derived from Pycnoporus sanguineus. Cinnabarin reduces rabies virus infection levels in neuroblastoma cells and causes cytopathic effects on neuroblastoma cell monolayers at high concentrations. Cinnabarin exhibits antibacterial activity against bacteria, with a preference for Gram-positive bacteria and human isolates. Cinnabarin can be used in studies related to rabies and drug-resistant Gram-positive bacteria .
    Cinnabarin
  • HY-133735
    GRP-60367
    1 Publications Verification

    		 RABV Infection
    GRP-60367 is a first-in-class small-molecule rabies virus (RABV) entry inhibitor with nanomolar potency against some RABV strains .
    GRP-60367
  • HY-144623
    Antiviral agent 15

    		SARS-CoV Infection
    Antiviral agent 15 (Compound 15f) is a Clofazimine derivative with antiviral effects. Antiviral agent 15 inhibits both rabies virus and pseudo-typed SARS-CoV-2 with EC50 values of 1.45 μM and 14.6 μM, respectively .
    Antiviral agent 15
  • HY-P4129
    Rabies Virus Matrix Protein Fragment(RV-MAT)

    		nAChR Others
    Rabies Virus Matrix Protein Fragment (RV-MAT) is a polypeptide. Rabies Virus Matrix Protein Fragment targets the acetylcholine receptor (AChR) that exists on the cell surface .
    Rabies Virus Matrix Protein Fragment(RV-MAT)
  • HY-172704
    DSPE-PEG1000-RVG29

    		Liposome nAChR Cancer
    DSPE-PEG1000-RVG29 is a PEG compound which composed of DSPE and a Rabies virus glycoprotein 29 (RVG29). RVG29 can bind specifically to the nicotinic acetylcholine receptor (nAChR) at the blood-brain barrier (BBB) and cross over the BBB .
    DSPE-PEG1000-RVG29
  • HY-159744
    Liposomal adjuvant (M103)

    		Toll-like Receptor (TLR) Inflammation/Immunology
    Liposomal adjuvant (M103) is mainly composed of phospholipids and prepared with highly purified immunostimulatory substances (polysaccharides), with a pH value of 6.2-6.8. This adjuvant is safe, non-toxic, and metabolizable. It can induce cellular and humoral immunity, has a sustained-release effect, and can prolong the residence time of antigens in the body. This adjuvant is suitable for various veterinary vaccines, including inactivated vaccines and genetically engineered subunit vaccines. It is recommended for use in rabies, porcine circovirus, , foot-and-mouth disease (FMD), and blue ear disease, etc.
    Liposomal adjuvant (M103)
  • HY-172705A
    DSPE-PEG3400-RVG29

    		Liposome nAChR Infection
    DSPE-PEG3400-RVG29 is a PEG conjugate composed of DSPE and rabies virus glycoprotein 29 (RVG29). RVG29 specifically binds to nicotinic acetylcholine receptors (nAChR) at the blood-brain barrier (BBB), crosses the BBB, and mediates receptor-dependent transcytosis. DSPE-PEG3400-RVG29 can be used for brain-targeted drug delivery, surface modification of nanocarriers, as well as gene and nucleic acid delivery. DSPE-PEG3400-RVG29 is applicable to research related to hypoxic-ischemic brain injury, Parkinson's disease, and other conditions
    DSPE-PEG3400-RVG29
  • HY-182464
    DABMA

    		Potassium Channel Infection Others
    DABMA is a TMEM175 channel activator with a human EC50 of 17.9 μM. DABMA directly increases TMEM175 channel current via interaction with intracellular, transmembrane, or endosomal lumen-associated domains, and does not alter TMEM175 mRNA or protein levels. DABMA delays endolysosomal substrate degradation, modulates endolysosomal trafficking, increases acidic organelle accumulation, induces cholesterol accumulation and altered late endosome morphology. DABMA can be used for the research of coronavirus disease, Clostridium difficile infection, Pseudomonas aeruginosa infection, rabies, and influenza virus infection .
    DABMA
  • HY-107620R
    PD 198306 (Standard)

    		Reference Standards MEK Neurological Disease
    PD 198306 (Standard) is the analytical standard of PD 198306 (HY-107620). This product is intended for research and analytical applications. PD 198306 is a selective MAPK/ERK-Kinase (MEK) inhibitor. PD 198306 results in an observable reduction in the Streptozocin induced increase in the level of active ERK1 and 2. Antihyperalgesic effects .
    PD 198306 (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: